LC
NRIX icon

Lindbrook Capital’s Nurix Therapeutics NRIX Stock Holding History

Lindbrook Capital’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-19
Closed -$427 – 2869
2024
Q3 		$427 Sell
19
-2
-10% -$45 ﹤0.01% 2707
2024
Q2 		$438 Buy
+21
New +$327 ﹤0.01% 2653
2023
Q4 		– Sell
-333
Closed -$2.62K – 2778
2023
Q3 		$2.62K Buy
333
+159
+91% +$1.45K ﹤0.01% 2027
2023
Q2 		$1.74K Sell
174
-129
-43% -$1.32K ﹤0.01% 2205
2023
Q1 		$2.69K Buy
303
+144
+91% +$1.5K ﹤0.01% 2115
2022
Q4 		$1.75K Buy
159
+34
+27% +$410 ﹤0.01% 2284
2022
Q3 		$2K Hold
125
– – ﹤0.01% 2102
2022
Q2 		$2K Buy
125
+9
+8% +$102 ﹤0.01% 2012
2022
Q1 		$2K Buy
+116
New +$2.06K ﹤0.01% 2037

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Lindbrook Capital's NRIX Position: Q4 2024 in Review

Lindbrook Capital sold out of Nurix Therapeutics (NRIX) in Q4 2024, closing a stake of 19 shares — an estimated $427 sold.

Lindbrook Capital first reported a position in NRIX in Q1 2022 and held it in 9 quarters. The position peaked at $2.69K in Q1 2023. 175 funds tracked by Wall St. Rank hold NRIX as of Q4 2024.

  • Lindbrook Capital reported no remaining Nurix Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Lindbrook Capital sold 19 Nurix Therapeutics shares in Q4 2024, an estimated $427.
  • Lindbrook Capital first reported a position in Nurix Therapeutics in Q1 2022 and held it in 9 quarters.
  • Lindbrook Capital's Nurix Therapeutics position peaked at $2.69K in Q1 2023.
  • 175 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2024.

Based on Lindbrook Capital's 13F filing for Q4 2024, filed 6 Feb 2025.